FAQ

MART-1 Antigen (vaccine component)

Known as: MelanA, Melan A, MART-1 Antigen 
A protein found on normal melanocytes (cells that make the pigment melanin) in the skin and in the retina. It is also found on most melanomas… (More)

Topic mentions per year

Topic mentions per year

1995-2017
05101519952017

Related topics

Related topics

2 relations

Broader (1)

MART-1 Antigen
MLANA gene

Related mentions per year

Related mentions per year

1995-2018
1990200020102020
MART-1 Antigen (vaccine component)
MART-1 Antigen
MLANA gene

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Highly Cited
2007
Highly Cited
2007
Depletion of CD4+CD25+ human regulatory T cells in vivo: kinetics of Treg depletion and alterations in immune functions in vivo and in vitro.
The aim of this study was to investigate whether depletion of CD4(+)CD25(+) regulatory T cells (Treg) from melanoma patients… (More)
Is this relevant?
Highly Cited
2006
Highly Cited
2006
Dendritic cells loaded with killed allogeneic melanoma cells can induce objective clinical responses and MART-1 specific CD8+ T-cell immunity.
Dendritic cells (DCs) loaded with killed allogeneic tumors can cross-prime tumor-specific naive CD8 T cells in vitro, thereby… (More)
Is this relevant?
Highly Cited
2005
Highly Cited
2005
Novel genes associated with malignant melanoma but not benign melanocytic lesions.
PURPOSE Cutaneous melanoma is a common, aggressive cancer with increasing incidence. The identification of melanoma-specific… (More)
  • figure 1
  • figure 2
  • table 2
  • figure 3
Is this relevant?
Highly Cited
2003
Highly Cited
2003
MLANA/MART1 and SILV/PMEL17/GP100 are transcriptionally regulated by MITF in melanocytes and melanoma.
The clinically important melanoma diagnostic antibodies HMB-45, melan-A, and MITF (D5) recognize gene products of the melanocyte… (More)
Is this relevant?
Highly Cited
2001
Highly Cited
2001
Immune and clinical responses in patients with metastatic melanoma to CD34(+) progenitor-derived dendritic cell vaccine.
Immunization to multiple defined tumor antigens for specific immune therapy of human cancer has thus far proven difficult… (More)
  • figure 1
  • table 1
  • figure 2
  • table 2
  • figure 3
Is this relevant?
Highly Cited
2001
Highly Cited
2001
A comparison of two types of dendritic cell as adjuvants for the induction of melanoma-specific T-cell responses in humans following intranodal injection.
Dendritic cells (DCs) elicit potent anti-tumoral T-cell responses in vitro and in vivo. However, different types of DC have yet… (More)
Is this relevant?
2001
2001
Immunization of HLA-A2+ melanoma patients with MAGE-3 or MelanA peptide-pulsed autologous peripheral blood mononuclear cells plus recombinant human interleukin 12.
Vaccination with dendritic cells (DCs) pulsed with tumor antigen peptides has shown promise in the treatment of melanoma… (More)
Is this relevant?
Highly Cited
1999
Highly Cited
1999
Humoral immune responses of cancer patients against "Cancer-Testis" antigen NY-ESO-1: correlation with clinical events.
Humoral immune responses against the "Cancer-Testis" (CT) antigen NY-ESO-1 are frequently observed in patients with NY-ESO-1… (More)
Is this relevant?
Highly Cited
1997
Highly Cited
1997
Immunoselection in vivo: independent loss of MHC class I and melanocyte differentiation antigen expression in metastatic melanoma.
Peptides derived from melanocyte differentiation antigens have been identified as targets for MHC class I-restricted cytolytic T… (More)
Is this relevant?
Highly Cited
1996
Highly Cited
1996
Inverse relationship of melanocyte differentiation antigen expression in melanoma tissues and CD8+ cytotoxic-T-cell responses: evidence for immunoselection of antigen-loss variants in vivo.
Antigenic peptides derived from differentiation antigens of the melanocyte lineage were recently identified in human melanomas as… (More)
Is this relevant?